Multimodal brain data foundation
VergeDB aggregates multimodal patient brain data collected over more than a decade, including transcriptomic, genetic, proteomic, single-cell, biomarker, and clinical annotations.
Verge Labs
RevendiquerVerge Labs is an AI platform for human biology focused on neurological disease. It combines proprietary multimodal brain data with foundation models to support target discovery, biomarker work, patient stratification, and trial optimization.
Frontier AI for human biology, starting with the brain
Verge Labs is an AI platform for human biology with a specific focus on neuroscience and neurological disease. It combines a proprietary multimodal patient brain dataset with foundation models built to reason about patient biology, then applies those models to drug discovery and clinical development workflows.
The core product story is anchored in human tissue rather than proxy data alone. VergeDB includes brain tissue, genetics, clinical annotations, and other molecular layers drawn from thousands of patients, while vBx-1.0 and CONVERGE turn that data into patient-level predictions for target selection, biomarker discovery, patient stratification, and trial design.
Platform capabilities
Patient-level foundation models
vBx-1.0 links brain biology, longitudinal biofluids, and clinical trajectory into a unified patient representation, then infers brain state from accessible inputs such as blood, imaging, and clinical attributes.
Target discovery from human tissue
The platform can surface causal disease signatures and identify genes that, when modulated, may shift a patient’s brain state toward health.
Patient stratification and biomarker work
CONVERGE stratifies cohorts by molecular endotype rather than diagnosis to find the patients most likely to benefit and the biomarkers likely to move earliest.
Program enablement workflows
Program teams can use the platform to stress-test preclinical and translational decisions against real human patient biology, including indication expansion questions.
Customizable to a program
The model can be fine-tuned with program- and trial-specific data to sharpen accuracy for individual molecules and study contexts.
Where the platform is used
Novel target discovery
Teams can use the platform to identify genes and pathways that are most likely to change disease biology in human brain tissue, rather than relying only on animal proxies.
Program enablement
Once a target is chosen, program teams can assess whether the biology translates across patient subgroups, preclinical models, and indications before moving deeper into development.
Clinical trial optimization
Clinical teams can stratify trial populations by molecular endotype and identify biomarkers that should move early in response to treatment.
Patient-level molecular inference
Scientists can infer brain molecular state from blood, imaging, and clinical attributes to obtain a virtual biopsy when direct tissue sampling is not possible.
Human disease modeling
Research teams can use the dataset to study disease signatures across multimodal human samples and annotate how biology varies over time and across patient groups.
Pros and Cons
Pros
- Built on a large proprietary human brain dataset assembled over a decade.
- Uses paired multimodal evidence from tissue, blood, genetics, imaging, and clinical annotations.
- Supports multiple stages of neuroscience R&D, from target discovery to trial optimization.
- Frames predictions at the patient level rather than at isolated cell or protein level.
- Can be fine-tuned with program- and trial-specific data.
Cons
- The publicly visible pricing page is a 404, so commercial terms are not disclosed in the provided sources.
- The source is heavily focused on neurological disease, so evidence for use beyond neuroscience is limited.
FAQ
What does Verge Labs focus on?
Verge Labs presents the platform as starting with the brain and using multimodal human tissue, blood, genetics, imaging, and clinical data to reason about neurological disease at the patient level.
Who is the platform for?
The platform is aimed at drug developers working in neuroscience and precision neurology, especially teams deciding which targets to pursue, which patients to study, and how to structure trials.
What is a virtual biopsy in this context?
The source describes vBx-1.0 as a foundation model that can infer molecular brain state from more accessible modalities such as blood, imaging, and clinical attributes, producing a virtual biopsy of the brain.
What kinds of work does the platform support?
The platform is positioned for target discovery, target characterization, biomarker identification, patient stratification, program enablement, and clinical trial optimization.
Is pricing published on the site?
The pricing page at the provided URL returns a 404, so the source does not provide pricing details.
Quick Facts
- Category
- AI platform for human biology
- Primary focus
- Neuroscience and neurological disease
- Core platform names
- VergeDB, vBx-1.0, CONVERGE
- Data scale
- 12,000+ brains and 6,000+ patients/controls
- Source domain
- vergegenomics.com
- Pricing
- Not publicly listed; pricing URL returns 404